Contineum Therapeutics Valuation Multiples

Contineum Therapeutics Overview

About Contineum Therapeutics

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Founded

2009

HQ

Employees

41

Website

contineum-tx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2M

EBITDA: ($74M)

EV

$381M

Valuation Multiples

Multiples.vc

Start free trial

Contineum Therapeutics Financials

Contineum Therapeutics reported last 12-month revenue of $2M and negative EBITDA of ($74M).

In the same LTM period, Contineum Therapeutics generated $2M in gross profit, ($74M) in EBITDA losses, and had net loss of ($62M).

Contineum Therapeutics P&L

In the most recent fiscal year, Contineum Therapeutics reported revenue of — and EBITDA of ($42M).

Contineum Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Contineum Therapeutics Stock Performance

Contineum Therapeutics has current market cap of $558M, and enterprise value of $381M.

Contineum Therapeutics' stock price is $15.27.

Contineum Therapeutics Valuation Multiples

Contineum Therapeutics trades at 182.0x EV/Revenue multiple, and (5.2x) EV/EBITDA.

Contineum Therapeutics Financial Valuation Multiples

As of March 15, 2026, Contineum Therapeutics has market cap of $558M and EV of $381M.

Equity research analysts estimate Contineum Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Contineum Therapeutics has a P/E ratio of (8.9x).

Contineum Therapeutics Margins & Growth Rates

Contineum Therapeutics' revenue in the last 12 month grew by 329%.

Contineum Therapeutics' revenue per employee in the last FY averaged $0.1M.

Contineum Therapeutics' rule of 40 is (3188%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Contineum Therapeutics' rule of X is (2695%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Contineum Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Contineum Therapeutics M&A Activity

Contineum Therapeutics acquired XXX companies to date.

Last acquisition by Contineum Therapeutics was on XXXXXXXX, XXXXX. Contineum Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Contineum Therapeutics Investment Activity

Contineum Therapeutics invested in XXX companies to date.

Contineum Therapeutics made its latest investment on XXXXXXXX, XXXXX. Contineum Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).